Literature DB >> 3871765

Fluoxetine: clinical pharmacology and physiologic disposition.

L Lemberger, R F Bergstrom, R L Wolen, N A Farid, G G Enas, G R Aronoff.   

Abstract

Fluoxetine (30 mg), administered for 7 days to normal volunteers, produced a 66% inhibition of tritiated serotonin uptake into platelets. Plasma concentrations of fluoxetine correlated positively with inhibition of serotonin uptake. Fluoxetine is well absorbed after oral administration in both the fed and fasted states and demonstrates dose proportionality. Fluoxetine disappears from plasma with a half-life of 1-3 days; its metabolite norfluoxetine has a plasma half-life of 7-15 days. After administration of 14C-fluoxetine, approximately 65% of the administered dose of radioactivity is recovered in urine and about 15% in feces. Fluoxetine, given as a single dose or in multiple doses over 8 days, did not produce significant effects on the plasma disappearance of warfarin, diazepam, tolbutamide, or chlorothiazide. Coadministration of fluoxetine and ethanol did not result in an increase from control values in the blood ethanol levels, nor did it produce significant changes in physiologic, psychometric, or psychomotor activity. Pharmacokinetics of fluoxetine in the elderly and normal volunteers appear to be similar. In addition, pharmacokinetic analyses in patients with varying degrees of renal impairment did not show significant differences from healthy subjects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871765

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  34 in total

Review 1.  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Authors:  M J Burke; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

2.  Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports.

Authors:  P Jalil
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

3.  Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine.

Authors:  T A Lasher; J C Fleishaker; R C Steenwyk; E J Antal
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 4.  Selective serotonin reuptake inhibitors in older patients. A tolerability perspective.

Authors:  U Skerritt; R Evans; S A Montgomery
Journal:  Drugs Aging       Date:  1997-03       Impact factor: 3.923

Review 5.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

6.  Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption.

Authors:  K Balon; B U Riebesehl; B W Müller
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

Review 7.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs.

Authors:  M V Rudorfer; W Z Potter
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 9.  Clinical pharmacokinetics of fluoxetine.

Authors:  A C Altamura; A R Moro; M Percudani
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

10.  Fluoxetine overdose-induced seizure.

Authors:  Jeffrey R Suchard
Journal:  West J Emerg Med       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.